Sarcopenic obesity in ageing: cardiovascular outcomes and mortality.
Janice C AtkinsS Goya WannamatheePublished in: The British journal of nutrition (2020)
Obesity is a major public health issue with prevalence increasing worldwide. Obesity is a well-established risk factor for CVD and mortality in adult populations. However, the impact of being overweight or obese in the elderly on CVD and mortality is controversial. Some studies even suggest that overweight and obesity, measured by BMI, are apparently associated with a decreased mortality risk (known as the obesity paradox). Ageing is associated with an increase in visceral fat and a progressive loss of muscle mass. Fat mass is positively associated and lean mass is negatively associated with risk of mortality. Therefore, in older adults BMI is not a good indicator of obesity. Sarcopenia has been defined as the degenerative loss of muscle mass, quality and strength with age and is of major concern in ageing populations. Sarcopenia has previously been associated with increased risks of metabolic impairment, cardiovascular risk factors, physical disability and mortality. It is possible for sarcopenia to co-exist with obesity, and sarcopenic obesity is a new class of obesity in older adults who have high adiposity levels together with low muscle mass, quality or strength. Therefore, sarcopenia with obesity may act together to increase their effect on metabolic disorders, CVD and mortality. This review will discuss the available evidence for the health implications of sarcopenic obesity on CVD and mortality in older adults.
Keyphrases
- insulin resistance
- weight loss
- metabolic syndrome
- weight gain
- type diabetes
- high fat diet induced
- public health
- cardiovascular events
- adipose tissue
- skeletal muscle
- physical activity
- bariatric surgery
- risk factors
- body mass index
- cardiovascular risk factors
- mental health
- healthcare
- coronary artery disease
- quality improvement
- fatty acid
- body composition
- community dwelling